Business
After years of contraction, investors see biotech reentering a growth cycle driven by scientific progress, asset quality and renewed conviction in oncology, obesity and neuroscience innovation.
FEATURED STORIES
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Privately-held Rain Therapeutics closed a $63 million Series B financing round that will be used to advance the company’s pipeline of targeted cancer therapies, including RAIN-32, its recently acquired asset from Daiichi Sankyo.
GlaxoSmithKline has opened a new $13 million research hub in London focused on artificial intelligence.
Months after forging a development partnership for a COVID-19 vaccine, GlaxoSmithKline and Sanofi are moving their adjuvanted vaccine candidate into the clinic.
Recently, the U.S. Centers for Disease Control and Prevention (CDC) made a regular data update on COVID-19 deaths. Unfortunately, the data, and how it was presented, was immediately misinterpreted.
Biospace recently analyzed key emerging cell and gene therapy companies to get a handle on how this evolving science is beginning to make its way from research into clinical applications.
Biopharma and life science companies from across the globe provide updates on their pipelines and businesses.
In an 8-K filing with the U.S. Securities and Exchange Commission, Intercept Pharmaceuticals said it will eliminate approximately 170 employees as part of an effort to streamline the company’s operations and reduce operating expenses.
A new 10,000 square foot facility in Marlborough, MA will allow StageBio to offer their expanded histopathology expertise and grow the company’s reach across the greater Boston region.
Gilead Sciences and Jounce Therapeutics entered a discovery and development deal to exclusively license Jounce’s JTX-1811 immuno-oncology program.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 2, 2020.